SFDA Closes Down Shanghai Hualian Pharmaceutical
This article was originally published in PharmAsia News
China's State FDA has announced that it has revoked the drug production license and approval number of Shanghai Hualian Pharmaceutical. The company, a subsidiary of Shanghai Pharmaceutical Group, has been in the news recently for its adulterated methotrexate drugs which adversely affected some leukemia patients across China. Some of Shanghai Hualian's key products enjoy a 50 percent share of China's domestic market. Analysts note that SFDA's clamp down on a long-established national enterprise sends out strong signals and a warning to the drug manufacturing industry that the government will not compromise on food and drug safety. (Click here for more - Chinese Language)
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.